NCT04820972.

Study name	Early‐start antiplatelet treatment after neurosurgery in patients with spontaneous intracerebral haemorrhage
Methods	Design: randomised controlled PROBE parallel group trial Setting: multicentre in China Dates: 1 May 2021 to May 2023
Participants	Sample size: 250 participants Diagnosis: post‐operative ICH Inclusion criteria 18‐70 years old Nontraumatic spontaneous ICH Postoperative patients with high risk of major adverse cardiac/cerebrovascular and peripheral vessel events (MACCPE): previous history of cerebral infarction or TIA previous history of coronary heart disease or myocardial infarction use ASCVD Risk Estimator Plus (http://tools.acc.org/ASCVD‐Risk‐Estimator‐Plus/#!/calculate/estimate/) to assess the risk of ischaemic events for patients with no previous history of cerebral infarction, TIA, or coronary heart diseases or myocardial infarction, 10 years risk > 10% is defined as a high risk of cardiovascular ischaemic events The Caprini Risk Scale is used to assess the risk of venous thrombosis in the lower extremities. Score > 2 is defined as a high risk of venous thrombosis Patients who received neurosurgical procedures to remove the haematoma, including craniotomy, endoscopic haematoma removal and haematoma aspiration Patients who signed informed consent No history of allergy to salicylic acid preparation Patients who complete the preintervention assessment and meet these criteria: postoperative head CT showed no new infarction or haemorrhage postoperative venous ultrasound of the lower extremity did not reveal deep vein thrombosis postoperative electrocardiogram and myocardial enzyme examination did not show acute myocardial ischaemia or myocardial infarction Exclusion criteria There are structural cerebrovascular lesions (such as intracranial aneurysms, cerebrovascular malformations, etc) or tumours in the area of bleeding or the bleeding is suspected to be related to these lesions Ischaemic stroke with haemorrhagic conversion Secondary bleeding due to venous embolism A malignant tumour and expected to have a survival of no more than 3 months Taking antithrombotic agents (vitamin K antagonists (warfarin,) new anticoagulants (dabigatran or rivaroxaban)) in addition to antiplatelet agents Previous history of thrombocytopaenia or coagulation disorders Previous history of AF
Interventions	Intervention: aspirin 100 mg once daily antiplatelet therapy starting from the third day after surgery Comparator: 'traditional'
Outcomes	Primary outcomes Intracranial haemorrhage Major adverse cardiac/cerebrovascular and peripheral vessel events Secondary outcomes: none specified Duration of follow‐up: 90 days
Starting date	1 May 2021
Contact information	JUN WU, MD wujunslf@126.com Shuo Wang, MD captain9858@126.com
Notes	Declarations of interest: not specified in trials register Sources of funding: not specified in trials register